Related Experiment Video
Updated: Oct 21, 2025

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina
Published on: March 14, 2025
Quantification of 2-NBDG, a probe for glucose uptake, in GLUT1 overexpression in HEK293T cells by LC-MS/MS
Yanhong Sun1, Minwan Hu1, Fenghe Wang1
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Drug Metabolism, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Abstract:
The growth and proliferation of most cancer cells involve the excessive uptake of glucose mediated by glucose transporters. An effective strategy for cancer therapy has been to inhibit the GLUTs that are usually overexpressed in a variety of tumor cells. 2-NBDG is a GLUT1 substrate that can be used as a probe for GLUT1 inhibitors. An accurate and simple assay for 2-NBDG in a HEK293T cell model overexpressing GLUT1 was developed using liquid chromatography-tandem mass spectrometry. Chromatographic separation was achieved using a Xbridge® Amide column (3.5 μm, 2.1 mm × 150 mm, Waters) with acetonitrile-water containing 2 μM ammonium acetate (80:20, v/v) at a flow rate of 0.25 mL/min. Mass detection was conducted in the parallel reaction monitoring (PRM) mode. The calibration curve for 2-NBDG showed good linearity in the concentration range of 5-500 ng/mL with satisfactory precision, a relative standard deviation ranging from 2.92 to 9.59% and accuracy with a relative error ranging from -13.14 to 7.34%. This method was successfully applied to quantify the uptake of GLUT1-mediated 2-NBDG, and the results clearly indicated inhibition of GLUT1 by WZB117 and quercetin (two potent glucose transporter inhibitors) in the GLUT1-HEK293T cell model. This study provides a convenient and accurate method for high-throughput screening of selective and promising GLUT1 inhibitors.
Insights
Researchers developed a new assay to measure glucose transporter 1 (GLUT1) activity. This method accurately quantifies 2-NBDG uptake and identifies potential GLUT1 inhibitors for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Cancer cells exhibit increased glucose uptake via glucose transporters (GLUTs).
- Inhibiting GLUTs is a promising cancer therapeutic strategy.
- 2-NBDG serves as a probe for studying GLUT1 inhibitors.
Purpose of the Study:
- To develop an accurate and simple assay for quantifying 2-NBDG in a GLUT1-overexpressing cell model.
- To validate the assay's utility in identifying GLUT1 inhibitors.
Main Methods:
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed.
- A Xbridge® Amide column was used for chromatographic separation.
- Parallel Reaction Monitoring (PRM) mode was utilized for mass detection.
Main Results:
- A linear calibration curve for 2-NBDG (5-500 ng/mL) with good precision and accuracy was established.
- The assay successfully quantified GLUT1-mediated 2-NBDG uptake.
- Inhibition of GLUT1 by WZB117 and quercetin was confirmed.
Conclusions:
- A convenient and accurate LC-MS/MS method for 2-NBDG quantification was developed.
- This assay facilitates high-throughput screening of selective GLUT1 inhibitors.
- The findings support the development of novel cancer therapeutics targeting GLUT1.
More Related Videos
06:28A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood
Published on: August 12, 2016
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017